The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will review two new technologies to help treat heart failure (HF) Oct. 8-9, 2013.

Abbott promised preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack. [1] The test could be particularly beneficial for women, who may have different presenting symptoms and are often under-diagnosed. [2] The study, which is being conducted by researchers at the University of Edinburgh, is evaluating Abbott's Architect Stat High Sensitive Troponin-I (hsTnI) test, which received CE mark in January 2013.

UltraSPECT announced that MaineHealth, a family of hospitals and medical centers throughout Maine, has selected the UltraSPECT Xpress.Cardiac and Xpress3.Cardiac solutions as part of the organization’s strategy for reducing nuclear medicine (NM) dose and complying with the American Society of Nuclear Cardiology (ASNC) final guidelines effective Jan. 1, 2014. Maine Medical Partners (MMP) – MaineHealth Cardiology in South Portland is one of ten facilities within MaineHealth that is installing the product, with others scheduled to continue roll out before the end of 2013.